| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CellSeed Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥785.00 |
| 52 Week High | JP¥1,160.00 |
| 52 Week Low | JP¥201.00 |
| Beta | 0 |
| 11 Month Change | -4.96% |
| 3 Month Change | 239.83% |
| 1 Year Change | 91.93% |
| 33 Year Change | 229.83% |
| 5 Year Change | 56.69% |
| Change since IPO | -42.95% |
Recent News & Updates
Shareholder Returns
| 7776 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -6.3% | 7.1% | 2.7% |
| 1Y | 91.9% | 16.5% | 10.1% |
Return vs Industry: 7776 exceeded the JP Biotechs industry which returned 16.5% over the past year.
Return vs Market: 7776 exceeded the JP Market which returned 10.1% over the past year.
Price Volatility
| 7776 volatility | |
|---|---|
| 7776 Average Weekly Movement | 26.6% |
| Biotechs Industry Average Movement | 13.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in JP Market | 10.4% |
| 10% least volatile stocks in JP Market | 3.5% |
Stable Share Price: 7776's share price has been volatile over the past 3 months.
Volatility Over Time: 7776's weekly volatility has increased from 15% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Setsuko Hashimoto | www.cellseed.com |
CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware.
CellSeed Inc. Fundamentals Summary
| 7776 fundamental statistics | |
|---|---|
| Market cap | JP¥27.19b |
| Earnings (TTM) | -JP¥914.00m |
| Revenue (TTM) | JP¥161.00m |
0.0x
P/S Ratio0.0x
P/E RatioIs 7776 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7776 income statement (TTM) | |
|---|---|
| Revenue | JP¥161.00m |
| Cost of Revenue | JP¥98.00m |
| Gross Profit | JP¥63.00m |
| Other Expenses | JP¥977.00m |
| Earnings | -JP¥914.00m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 7776 perform over the long term?
See historical performance and comparison